[Sanders’ well-chronicled antagonism toward lobbyists has some
concerned they’ll be unable to blunt criticism of their clients’
profits or corporate executive salaries. ]
[[link removed]]

‘NOT BUSINESS AS USUAL’: HEALTH LOBBYISTS BRACE FOR BERNIE
SANDERS  
[[link removed]]


 

Megan R. Wilson
January 3, 2023
Politico
[[link removed]]


*
[[link removed]]
*
[[link removed]]
*
*
[[link removed]]

_ Sanders’ well-chronicled antagonism toward lobbyists has some
concerned they’ll be unable to blunt criticism of their clients’
profits or corporate executive salaries. _

Sen. Bernie Sanders (I-Vt.) has talked about working to boost access
to care, lower drug costs, expand the health care workforce and raise
wages., Francis Chung/POLITICO

 

Health care lobbyists representing insurers, drugmakers and a range of
powerful industry interests are steeling themselves for a Senate chair
immune to their usual charms — Bernie Sanders.

The Vermont independent is set to take over the Senate’s Health,
Education, Labor and Pensions Committee next month. Leading the panel
gives the Medicare-for-All proponent oversight authority over some of
his policy priorities — drug pricing, workers’ rights and income
inequality, and student and medical debt.

But Sanders’ well-chronicled antagonism toward lobbyists has some
concerned they’ll be unable to blunt criticism of their clients’
profits or corporate executive salaries. They are anxious Sanders
might seek to revive policies like importing drugs from Canada and
other nations, an idea loathed by drugmakers.

Lobbyists also worry they’ll struggle to get traction on any push to
make changes to a drug discount program involving pharmaceutical
companies and hospitals or revisit association health plans after a
Trump-era rule around them was voided.

“This will not be business as usual for K Street. It will be harder
for companies to get in and make a case,” said Michaeleen Crowell, a
lobbyist at lobbying and public affairs firm S-3 Group who served as
Sanders’ chief of staff for more than five years. “The culture in
the office is one where lobbyists are mistrusted, and they’re more
likely to discount what they hear directly from companies.”

POLITICO spoke to more than a dozen lobbyists and lawyers about having
Sanders at the helm of the HELP Committee, some of whom were granted
anonymity to talk about the senator’s dynamic with K Street.

Multiple lobbyists representing health insurers, pharmaceutical
companies, providers and health systems told POLITICO they’re going
to have to “bank shot” their advocacy to get their messages across
— lobbying other lawmakers on the committee and getting into the
ears of progressive policymakers and left-leaning organizations.

“There are ways to get things passively on his radar if you know him
well enough, if you know who he listens to or what he reads,”
Crowell said.

Sanders’ office declined to respond to questions from POLITICO,
including those about his relationship with lobbyists.

Lobbyists said another strategy could be working to insert favorable
provisions into larger bills, lean on the panel’s House counterpart,
the Energy and Commerce Committee, or go to Sen. Patty Murray
(D-Wash.), who is stepping down as HELP Committee chair to head the
Senate Appropriations Committee.

“It’s not status quo … we’re going to have to be creative with
patient groups to get him to listen,” said a lobbyist with health
system, health insurance and pharmaceutical clients granted anonymity
to speak freely. “If I’m going to be completely honest, we’re
still trying to figure out what we’re going to do.”

Sanders has talked about working to
[[link removed]]
boost access to care, lower drug costs, expand the health care
workforce and raise wages, and possibly reach across the aisle.
Sanders is also expected to push the jurisdictional bounds of the
committee, potentially taking on issues such as the health impacts of
climate change.

K Street will likely watch how often Sanders collaborates with the
committee’s incoming ranking member, Sen. Bill Cassidy (R-La.), as
the two have a history of working across the aisle. Although some
lobbyists have floated policies around drug pricing and surprise
billing as a possibility for them to find agreement, it’s not
entirely clear if they’ll end up on the same page.

“There’s a good chance the committee becomes a one-legged duck,
swimming in circles,” said a Republican lobbyist and former HELP
Committee staffer granted anonymity to speak freely.

But if the two end up aligning on some issues, that could be a
liability for some industry clients on K Street.

Jeff Forbes, co-founder of lobbying and public affairs firm Forbes
Tate, said Sanders has a history of bipartisanship, particularly while
chairing the Senate Veterans Affairs Committee, and will work to get
stuff done — “the question is going to be what, and at whose
expense?”

“Does corporate America have to worry? Of course they do,” he
added. “Between a populist Republican like Cassidy and a left-wing
chairman like Sanders, they’ll have plenty of anti-corporate areas
of mutual interest.”

[Bernie Sanders speaks while introducing health care legislation
titled the "Medicare for All Act of 2019" with Sen. Kirsten
Gillibrand (left).]
Bernie Sanders speaks while introducing health care legislation titled
the "Medicare for All Act of 2019" with Sen. Kirsten Gillibrand and
Sen. Jeff Merkley, during a news conference on Capitol Hill, April 9,
2019. | Mark Wilson/Getty Images

With the Senate majority comes subpoena power, and it’s almost
certain that health executives will be called to testify before the
committee — a reputational risk for corporations.

“Subpoena authority is certainly something that gets people paying
attention,” said Rafi Prober, co-head of the congressional
investigations practice at Akin Gump Strauss Hauer & Feld.

And conditions are ripe for the HELP Committee to beef up its hearings
schedule: The panel has only a few must-do items next session —
reauthorizing both pandemic preparedness legislation known as PAHPA
and an animal drug user fee bill — and Democratic priorities
aren’t expected to move, given the GOP-controlled House. This gives
Sanders the runway to dig into any issue he wants.

Most senior members of Congress have relationships with K Street
because lobbyists had worked for — or closely with — them while
serving as Capitol Hill aides, have donated to their campaigns or
otherwise have become close with their staff.

Sanders, meanwhile, isn’t rubbing elbows with executives and
lobbyists at fundraisers and doesn’t have a “kitchen cabinet” of
donor-advisers he talks with about policy, Crowell and others said.
He’s sworn off all money from political action committees — even
ones run by other senators and members of Congress — to his Senate
campaigns.

Further, most of his staffers have a mix of experience working for
him, progressive campaigns and nonprofits and share the aversion to
downtown corporate lobbyists.

“The prospects of a Sanders-led HELP committee are refreshing and
exciting,” said Craig Holman, a lobbyist at Public Citizen who works
on money-in-politics and ethics issues.

“The chairman will give everyone their due, including lobbyists
representing the public’s interest, without being swayed by campaign
cash,” he said. “Sanders’ new leadership position will help
build some equity between the influence of the haves and have-nots, of
which Public Citizen and other nonprofits more or less qualify as the
latter.”

But one Democratic lobbyist who advocates before the HELP Committee,
who was granted anonymity to speak candidly about the dynamic, said
Sanders’ staff members rarely take people’s meetings.

“It’s hard to find a lobbyist [who] has had much success working
with his staff. If the committee wants to be taken seriously on some
very important issues, they’re going to need to be more open to
talking with stakeholders — even ones [they] don’t like,” he
said.

Not all lobbyists are so down on their prospects. Michael Strazzella,
the leader of Buchanan Ingersoll & Rooney’s federal government
relations practice, said he is optimistic about working with Sanders
and his staff.

“He can be educated just like every other senator,” Strazzella
said. “Influence is a strong word, to be honest, but I do believe
that he is open to continuous education and understands the impact of
new policies. … I don’t think he’s necessarily set in his ways
about everything.”

Aside from his current staff, much of the dynamic with K Street will
depend on who he brings in to work on the committee, several lobbyists
told POLITICO.

Some hope it will be a departure from his traditional hiring patterns,
but one lobbyist who has relationships with Sanders’ health care
staff said he wants them to stick around.

“I just hope they stay because we at least know who we will be
working with next year and can have conversations with them,” said
the lobbyist, who was granted anonymity to speak about the
relationship, in an email. “I worry about the staff changing some
and not knowing any of the... players coming in and their approach to
interacting with downtown.”

_Ben Leonard contributed to this report. _

===

* Bernie Sanders; Senate Health
[[link removed]]
* Education
[[link removed]]
* Labor and Pensions Committee;
[[link removed]]

*
[[link removed]]
*
[[link removed]]
*
*
[[link removed]]

 

 

 

INTERPRET THE WORLD AND CHANGE IT

 

 

Submit via web
[[link removed]]

Submit via email
Frequently asked questions
[[link removed]]

Manage subscription
[[link removed]]

Visit xxxxxx.org
[[link removed]]

Twitter [[link removed]]

Facebook [[link removed]]

 




[link removed]

To unsubscribe, click the following link:
[link removed]